Inflamm-aging is a term used to describe the growing susceptibility of older people to chronic inflammation. This is mainly triggered by natural aging processes of the immune system and by oxidative cell stress resulting from excess levels of reactive oxygen species (ROS).
This development can cause a variety of diseases with inflammatory pathogenesis: Chronic degenerative diseases of aging such as osteoarthritis, cardiovascular diseases, type 2 diabetes and Alzheimer's dementia. In ageing societies people - men and women alike - suffer on average from at least one chronic disease for ten years at the end of their lives.
MetrioPharm's development focus is on inflamm-aging. Our goal is to develop safe and medically sophisticated anti-inflammatory therapies that allow people to maintain good health into old age.
Even in younger patients, inflammatory pathways can trigger chronic diseases: Autoimmune diseases such as psoriasis, rheumatoid arthritis, Crohn's disease or multiple sclerosis.
In the model indication psoriasis, the disease-modulating efficacy of the lead compound MP1032 was established in a Phase II study in 2019.